Utility of Survivin, BAP1, and Ki‑67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia

Kushitani,Kei; Amatya,Vishwa Jeet; Mawas,Amany Sayed; Suzuki,Rui; Miyata,Yoshihiro; Okada,Morihito; Inai,Kouki; Kishimoto,Takumi; Takeshima,Yukio

doi:10.3892/ol.2018.7765

Utility of Survivin, BAP1, and Ki‑67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia

Authors:
- Kei Kushitani
- Vishwa Jeet Amatya
- Amany Sayed Mawas
- Rui Suzuki
- Yoshihiro Miyata
- Morihito Okada
- Kouki Inai
- Takumi Kishimoto
- Yukio Takeshima
View Affiliations

Affiliations: Department of Pathology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan, Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, South Valley University, Qena 83523, Egypt, Department of Surgical Oncology, Research Center for Radiation Casualty Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734‑8551, Japan, Department of Internal Medicine, Okayama Rosai Hospital, Okayama 702‑8055, Japan
Published online on: January 10, 2018 https://doi.org/10.3892/ol.2018.7765
Pages: 3540-3547
Copyright: © Kushitani et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histological distinction between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) can be challenging. The aim of this study was to assess the diagnostic utility of Survivin, Ki‑67, and loss of BRCA1‑associated protein 1 (BAP1) expressions in distinguishing EM from RMH using immunohistochemistry. Formalin‑fixed, paraffin‑embedded specimens from 78 cases of EM and 80 cases of RMH were immunohistochemically examined for Survivin, BAP1, and Ki‑67. In addition, receiver operating characteristic curve analyses were performed to establish the cut‑off values for Survivin and Ki‑67 labelling indices. Survivin (cut‑off value: 5%) had 67.7% sensitivity and 100% specificity, while Ki‑67 (cut‑off value: 10%) had 85.1% sensitivity and 87.5% specificity, and BAP1 had 66.2% sensitivity and 100% specificity for the differentiation of EM from RMH. Among the combinations of two markers, the combination of Survivin and BAP1 (Survivin‑positive and/or BAP1‑loss finding) had the highest diagnostic accuracy (sensitivity: 89.8%; specificity: 100%; accuracy: 95.3%). We recommend using the combination of Survivin and BAP1 to distinguish EM from RMH.

View Figures

View References

1	Robinson BW, Musk AW and Lake RA: Malignant mesothelioma. Lancet. 366:397–408. 2005. View Article : Google Scholar : PubMed/NCBI
2	Roggli VL, Sharma A, Butnor KJ, Sporn T and Vollmer RT: Malignant mesothelioma and occupational exposure to asbestos: A clinicopathological correlation of 1445 cases. Ultrastruct Pathol. 26:55–65. 2002. View Article : Google Scholar : PubMed/NCBI
3	Delgermaa V, Takahashi K, Park EK, Le GV, Hara T and Sorahan T: Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 89:716–724. 2011. View Article : Google Scholar : PubMed/NCBI
4	Murayama T, Takahashi K, Natori Y and Kurumatani N: Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 49:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
5	Churg A, Roggli V, Galateau-Salle F, Cagle PhT, Gibbs AR, Hasleton PhS, Henderson DW, Vignaud JM, Inai K, Praet M, et al: Tumours of the pleuraWHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG: IARC Press; Lyon: pp. 153–181. 2015
6	Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, et al: Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 137:647–667. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ordóñez NG: Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: A review and update. Hum Pathol. 44:1–19. 2013. View Article : Google Scholar : PubMed/NCBI
8	Kushitani K, Amatya VJ, Okada Y, Katayama Y, Mawas AS, Miyata Y, Okada M, Inai K, Kishimoto T and Takeshima Y: Utility and pitfall of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma. Histopathology. 70:375–384. 2017. View Article : Google Scholar : PubMed/NCBI
9	Minato H, Kurose N, Fukushima M, Nojima T, Usuda K, Sagawa M, Sakuma T, Ooi A, Matsumoto I, Oda M, et al: Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am J Clin Pathol. 141:85–93. 2014. View Article : Google Scholar : PubMed/NCBI
10	Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H and Nabeshima K: BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests. Pathol Int. 66:563–570. 2016. View Article : Google Scholar : PubMed/NCBI
11	Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM and Churg A: Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 40:120–126. 2016. View Article : Google Scholar : PubMed/NCBI
12	McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN and Krausz T: BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol. 46:1670–1678. 2015. View Article : Google Scholar : PubMed/NCBI
13	Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, et al: BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 28:1043–1057. 2015. View Article : Google Scholar : PubMed/NCBI
14	Kimura F, Okayasu I, Kakinuma H, Satoh Y, Kuwao S, Saegusa M and Watanabe J: Differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells using the cell proliferation markers minichromosome maintenance protein 7, geminin, topoisomerase II alpha and Ki-67. Acta Cytol. 57:384–390. 2013. View Article : Google Scholar : PubMed/NCBI
15	Kimura F, Kawamura J, Watanabe J, Kamoshida S, Kawai K, Okayasu I and Kuwao S: Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: Can we differentiate reactive mesothelial cells from malignant cells? Diagn Cytopathol. 38:161–167. 2010.PubMed/NCBI
16	Hasteh F, Lin GY, Weidner N and Michael CW: The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 118:90–96. 2010. View Article : Google Scholar : PubMed/NCBI
17	Taheri ZM, Mehrafza M, Mohammadi F, Khoddami M, Bahadori M and Masjedi MR: The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 132:694–697. 2008.PubMed/NCBI
18	Churg A, Sheffield BS and Galateau-Salle F: New markers for separating benign from malignant mesothelial proliferations: Are we there yet? Arch Pathol Lab Med. 140:318–321. 2016. View Article : Google Scholar : PubMed/NCBI
19	Hiroshima K, Wu D, Hasegawa M, Koh E, Sekine Y, Ozaki D, Yusa T, Walts AE, Marchevsky AM, Nabeshima K, et al: Cytologic differential diagnosis of malignant mesothelioma and reactive mesothelial cells with fish analysis of p16. Diagn Cytopathol. 44:591–598. 2016. View Article : Google Scholar : PubMed/NCBI
20	Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN and Marchevsky AM: BAP1 immunostain and CDKN2A (p16) FISH analysis: Clinical applicability for the diagnosis of malignant mesothelioma in effusions. Diagn Cytopathol. 44:599–606. 2016. View Article : Google Scholar : PubMed/NCBI
21	Kushitani K, Amatya VJ, Mawas AS, Miyata Y, Okada M and Takeshima Y: Use of anti-noxa antibody for differential diagnosis between epithelioid mesothelioma and reactive mesothelial hyperplasia. Pathobiology. 83:33–40. 2016. View Article : Google Scholar : PubMed/NCBI
22	Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
24	Garg H, Suri P, Gupta JC, Talwar GP and Dubey S: Survivin: A unique target for tumor therapy. Cancer Cell Int. 16:492016. View Article : Google Scholar : PubMed/NCBI
25	Meerang M, Bérard K, Friess M, Bitanihirwe BK, Soltermann A, Vrugt B, Felley-Bosco E, Bueno R, Richards WG, Seifert B, et al: Low merlin expression and high survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. Mol Oncol. 10:1255–1265. 2016. View Article : Google Scholar : PubMed/NCBI
26	Hmeljak J, Erčulj N, Dolžan V, Pižem J, Kern I, Kovač V, Cemažar M and Cör A: Is survivin expression prognostic or predictive in malignant pleural mesothelioma? Virchows Arch. 462:315–321. 2013. View Article : Google Scholar : PubMed/NCBI
27	Chen S, Wang Y, An L, Fei ZT and Li T: The diagnostic value of survivin in malignant pleural effusion: A meta-analysis. Clin Chim Acta. 441:142–147. 2015. View Article : Google Scholar : PubMed/NCBI
28	Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, et al: Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer. 133:612–623. 2013. View Article : Google Scholar : PubMed/NCBI
29	De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y, Kauffman MG, Shacham S, et al: Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: The role of survivin. Oncotarget. 6:13119–13132. 2015. View Article : Google Scholar : PubMed/NCBI
30	Goričar K, Kovač V, Franko A, Dodič-Fikfak M and Dolžan V: Serum survivin levels and outcome of chemotherapy in patients with malignant mesothelioma. Dis Markers. 2015:3167392015. View Article : Google Scholar : PubMed/NCBI
31	Murali R, Wiesner T and Scolyer RA: Tumours associated with BAP1 mutations. Pathology. 45:116–126. 2013. View Article : Google Scholar : PubMed/NCBI
32	Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW and Müller J: Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 465:243–247. 2010. View Article : Google Scholar : PubMed/NCBI
33	Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, et al: The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 43:668–672. 2011. View Article : Google Scholar : PubMed/NCBI
34	Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al: Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 43:1022–1025. 2011. View Article : Google Scholar : PubMed/NCBI
35	Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, et al: Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 103:868–874. 2012. View Article : Google Scholar : PubMed/NCBI
36	Shinozaki-Ushiku A, Ushiku T, Morita S, Anraku M, Nakajima J and Fukayama M: Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma. Histopathology. 70:722–733. 2017. View Article : Google Scholar : PubMed/NCBI
37	Scholzen T and Gerdes J: The Ki-67 protein: From the known and the unknown. J Cell Physiol. 182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
38	Brown DC and Gatter KC: Monoclonal antibody Ki-67: Its use in histopathology. Histopathology. 17:489–503. 1990. View Article : Google Scholar : PubMed/NCBI
39	Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
40	Kim JY, Chung JY, Lee SG, Kim YJ, Park JE, Yoo KS, Yoo YH, Park YC, Kim BG and Kim JM: Nuclear interaction of Smac/DIABLO with survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells. Biochem Biophys Res Commun. 350:949–954. 2006. View Article : Google Scholar : PubMed/NCBI